Xenetic Biosciences, Inc. (XBIO) 10-Year Financial Performance & Capital Metrics

XBIO • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsHematologic Oncology

AboutXenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.Show more

Revenue $3M -1.6%
EBITDA -$4M +10.3%
Net Income -$4M +4.2%
EPS (Diluted) -2.57 +5.2%
Gross Margin 100%
EBITDA Margin -162.03% +8.9%
Operating Margin -168.16% +5.4%
Net Margin -158.39% +2.7%
ROE -50.12% -42.1%
ROIC -964.01% -93.9%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 171.1%
✓Trading at only 0.6x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Weak momentum: RS Rating 12 (bottom 12%)
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y171.13%

3Y29.15%

TTM13.3%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM22.59%

EPS CAGR

10Y-

5Y-

3Y-

TTM22.64%

ROCE

10Y Avg-81.91%

5Y Avg-51.46%

3Y Avg-44.56%

Latest-53.21%

Peer Comparison

Hematologic Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
INCYIncyte Corporation	20.66B	105.24	701.60	14.76%	24.69%	25.55%	1.21%	0.01
TGTXTG Therapeutics, Inc.	4.88B	30.71	204.73	40.8%	13.31%	21.87%		1.14
AGIOAgios Pharmaceuticals, Inc.	1.62B	27.80	2.39	36.07%	-8.96%	-31.24%		0.04
CLRBCellectar Biosciences, Inc.	15.48M	3.65	-0.09			-200.99%		0.03
CASICASI Pharmaceuticals, Inc.	21.37M	1.04	-0.41	-15.77%	-183.93%	-301.8%		11.96
VORVor Biopharma Inc.	308.06M	14.06	-0.41			-94.52%		0.33
FATEFate Therapeutics, Inc.	121.12M	1.05	-0.64	-78.55%	-21.87%	-66.69%		0.27
KPTIKaryopharm Therapeutics Inc.	121.95M	6.66	-0.71	-0.55%	-87.43%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	3M	7.58M	0	17.07K	436.94K	1.16M	1.71M	2.54M	2.5M
Revenue Growth %	-	-	1.53%	-1%	-	24.6%	1.66%	0.47%	0.49%	-0.02%
Cost of Goods Sold+	56.12K	36.45K	156.12K	15.83K	0	0	0	0	0	0
COGS % of Revenue	-	0.01%	0.02%	-	-	-	-	-	-	-
Gross Profit+	-56.12K	2.96M	7.43M	-15.83K	17.07K	436.94K	1.16M	1.71M	2.54M	2.5M
Gross Margin %	-	0.99%	0.98%	-	1%	1%	1%	1%	1%	1%
Gross Profit Growth %	-	53.81%	1.51%	-1%	2.08%	24.6%	1.66%	0.47%	0.49%	-0.02%
Operating Expenses+	9.82M	50.43M	11M	7.28M	12.9M	14.37M	6.91M	8.42M	7.06M	6.7M
OpEx % of Revenue	-	16.81%	1.45%	-	756.12%	32.9%	5.95%	4.94%	2.78%	2.68%
Selling, General & Admin	6.39M	6.69M	6.94M	4.39M	4.73M	3.4M	3.74M	3.65M	3.56M	3.42M
SG&A % of Revenue	-	2.23%	0.91%	-	277.23%	7.78%	3.23%	2.14%	1.4%	1.37%
Research & Development	3.43M	43.74M	4.06M	2.88M	4.89M	1.73M	3.16M	4.77M	3.49M	3.29M
R&D % of Revenue	-	14.58%	0.54%	-	286.5%	3.96%	2.73%	2.79%	1.38%	1.32%
Other Operating Expenses	0	0	-41.1K	-24.64K	3.28M	9.24M	0	0	0	0
Operating Income+	-9.82M	-47.43M	-3.57M	-7.28M	-12.89M	-13.94M	-5.75M	-6.72M	-4.52M	-4.2M
Operating Margin %	-	-15.81%	-0.47%	-	-755.12%	-31.9%	-4.95%	-3.94%	-1.78%	-1.68%
Operating Income Growth %	0.24%	-3.83%	0.92%	-1.04%	-0.77%	-0.08%	0.59%	-0.17%	0.33%	0.07%
EBITDA+	-9.77M	-47.39M	-3.54M	-7.26M	-12.86M	-13.91M	-5.71M	-6.69M	-4.52M	-4.05M
EBITDA Margin %	-	-15.8%	-0.47%	-	-753.51%	-31.83%	-4.92%	-3.92%	-1.78%	-1.62%
EBITDA Growth %	0.24%	-3.85%	0.93%	-1.05%	-0.77%	-0.08%	0.59%	-0.17%	0.33%	0.1%
D&A (Non-Cash Add-back)	56.12K	36.45K	23.78K	15.83K	27.49K	28.84K	35.48K	27.04K	0	153.34K
EBIT	-9.82M	-53.48M	-3.59M	-7.28M	-9.6M	-4.69M	-5.75M	-6.72M	-4.52M	-4.2M
Net Interest Income+	-265.31K	-729.54K	14.73K	0	108.49K	126.17K	100.47K	167.15K	355.76K	249.86K
Interest Income	1.69K	32	16.54K	0	108.49K	126.17K	100.47K	167.15K	355.76K	249.86K
Interest Expense	267K	729.57K	1.82K	24.13K	0	0	0	0	0	0
Other Income/Expense	-2.69M	-6.78M	-26.37K	-24.13K	111.8K	125.68K	101.59K	165.56K	381.14K	244.15K
Pretax Income+	-12.51M	-54.21M	-3.6M	-7.3M	-12.78M	-13.81M	-5.65M	-6.55M	-4.13M	-3.96M
Pretax Margin %	-	-18.07%	-0.47%	-	-748.57%	-31.61%	-4.86%	-3.84%	-1.63%	-1.58%
Income Tax+	0	0	26.37K	24.13K	0	-2.92M	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	0.79%	1%	1%	1%	1%
Net Income+	-12.51M	-54.21M	-3.6M	-7.3M	-12.78M	-10.89M	-5.65M	-6.55M	-4.13M	-3.96M
Net Margin %	-	-18.07%	-0.47%	-	-748.57%	-24.93%	-4.86%	-3.84%	-1.63%	-1.58%
Net Income Growth %	0.13%	-3.33%	0.93%	-1.03%	-0.75%	0.15%	0.48%	-0.16%	0.37%	0.04%
Net Income (Continuing)	-12.51M	-54.21M	-3.6M	-7.3M	-12.78M	-10.89M	-5.65M	-6.55M	-4.13M	-3.96M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-355.34	-875.41	-49.78	-96.57	-55.92	-17.04	-5.39	-4.49	-2.71	-2.57
EPS Growth %	0.15%	-1.46%	0.94%	-0.94%	0.42%	0.7%	0.68%	0.17%	0.4%	0.05%
EPS (Basic)	-355.34	-875.41	-49.78	-96.58	-55.92	-17.04	-5.39	-4.49	-2.71	-2.57
Diluted Shares Outstanding	35.2K	61.92K	72.21K	75.6K	285.25K	639.24K	1.03M	1.42M	1.53M	1.54M
Basic Shares Outstanding	35.2K	61.92K	72.21K	75.59K	285.25K	639.24K	1.03M	1.42M	1.53M	1.54M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	4.19M	8.34M	5.88M	1.19M	11.09M	12.37M	18.72M	13.65M	9.59M	6.59M
Cash & Short-Term Investments	132.23K	4.05M	5.53M	571.61K	10.37M	11.53M	18.24M	13.1M	8.98M	6.17M
Cash Only	132.23K	4.05M	5.53M	571.61K	10.37M	11.53M	18.24M	13.1M	8.98M	6.17M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	3M	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	365	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	66.51K	66.51K	99.51K	66.51K	527.08K	0	227.04K	0	603.83K	0
Total Non-Current Assets+	12.72M	12.64M	13.28M	13.24M	10.46M	809.99K	1.09M	1.07M	1.02M	313.92K
Property, Plant & Equipment	62.02K	42.37K	27.85K	4.96K	20.8K	27.04K	0	0	0	0
Fixed Asset Turnover	-	70.81x	272.39x	-	0.82x	16.16x	-	-	-	-
Goodwill	3.28M	3.28M	3.28M	3.28M	0	0	0	0	0	0
Intangible Assets	9.24M	9.24M	9.24M	9.24M	9.24M	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	129.31K	66.34K	724.71K	705.66K	1.19M	782.94K	1.09M	1.07M	1.02M	313.92K
Total Assets+	16.91M	20.97M	19.16M	14.43M	21.55M	13.18M	19.82M	14.72M	10.61M	6.9M
Asset Turnover	-	0.14x	0.40x	-	0.00x	0.03x	0.06x	0.12x	0.24x	0.36x
Asset Growth %	0.04%	0.24%	-0.09%	-0.25%	0.49%	-0.39%	0.5%	-0.26%	-0.28%	-0.35%
Total Current Liabilities+	7.34M	1.87M	1.94M	1.6M	1.42M	936.93K	1.42M	1.07M	809.59K	894.26K
Accounts Payable	1.79M	1.01M	786.78K	934.15K	931.13K	327.4K	362.47K	287.36K	240.83K	283.62K
Days Payables Outstanding	11.63K	10.08K	1.84K	21.54K	-	-	-	-	-	-
Short-Term Debt	4.05M	0	0	0	20.04K	0	0	0	0	0
Deferred Revenue (Current)	1000K	0	0	0	0	0	0	0	0	0
Other Current Liabilities	19.1K	20.2K	44.31K	218.03K	463.99K	0	0	39.95K	48.26K	34.2K
Current Ratio	0.57x	4.47x	3.03x	0.75x	7.84x	13.20x	13.18x	12.72x	11.84x	7.37x
Quick Ratio	0.57x	4.47x	3.03x	0.75x	7.84x	13.20x	13.18x	12.72x	11.84x	7.37x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	2.96M	2.94M	2.92M	2.92M	2.92M	27.04K	0	0	0	0
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	27.04K	0	0	0	0
Deferred Tax Liabilities	2.92M	2.92M	2.92M	2.92M	2.92M	0	0	0	0	0
Other Non-Current Liabilities	38.79K	19.88K	0	0	0	0	0	0	0	0
Total Liabilities	10.3M	4.8M	4.86M	4.52M	4.33M	963.97K	1.42M	1.07M	809.59K	894.26K
Total Debt+	395K	0	0	0	20.04K	62.52K	27.04K	0	0	0
Net Debt	262.77K	-4.05M	-5.53M	-571.61K	-10.35M	-11.47M	-18.22M	-13.1M	-8.98M	-6.17M
Debt / Equity	0.06x	-	-	-	0.00x	0.01x	0.00x	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-36.79x	-65.01x	-1963.02x	-301.53x	-	-	-	-	-	-
Total Equity+	6.61M	16.17M	14.3M	9.91M	17.21M	12.22M	18.39M	13.65M	9.8M	6.01M
Equity Growth %	-0.37%	1.45%	-0.12%	-0.31%	0.74%	-0.29%	0.51%	-0.26%	-0.28%	-0.39%
Book Value per Share	187.75	261.13	198.04	131.12	60.35	19.11	17.89	9.59	6.41	3.90
Total Shareholders' Equity	6.61M	16.17M	14.3M	9.91M	17.21M	12.22M	18.39M	13.65M	9.8M	6.01M
Common Stock	162.01K	8.73K	9.04K	9.73K	6.09K	8.77K	13.46K	1.52K	1.54K	1.54K
Retained Earnings	-88.13M	-142.34M	-145.93M	-153.23M	-166.01M	-176.9M	-182.55M	-189.1M	-193.23M	-197.19M
Treasury Stock	-5.28M	-5.28M	-5.28M	-5.28M	-5.28M	-5.28M	-5.28M	-5.28M	-5.28M	-5.28M
Accumulated OCI	253.73K	253.73K	253.73K	253.73K	253.73K	253.73K	253.73K	253.73K	253.73K	253.73K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-5.3M	-8.79M	1.49M	-6.46M	-6.4M	-4.27M	-4.74M	-4.65M	-4.11M	-2.82M
Operating CF Margin %	-	-2.93%	0.2%	-	-374.98%	-9.77%	-4.08%	-2.72%	-1.62%	-1.13%
Operating CF Growth %	0.57%	-0.66%	1.17%	-5.33%	0.01%	0.33%	-0.11%	0.02%	0.11%	0.32%
Net Income	-12.51M	-54.21M	-3.6M	-7.3M	-12.78M	-10.89M	-5.65M	-6.55M	-4.13M	-3.96M
Depreciation & Amortization	56.12K	36.45K	23.78K	15.83K	27.49K	28.84K	35.48K	27.04K	0	0
Stock-Based Compensation	2.75M	2.1M	1.92M	1.42M	853.52K	468.91K	410.44K	511.48K	0	171.81K
Deferred Taxes	2.6M	-1.58M	0	0	0	-2.92M	-24.27K	0	0	0
Other Non-Cash Items	834K	49.11M	-126.32K	-5.23K	6.38M	9.1M	24.27K	1.79M	283.08K	0
Working Capital Changes	965.14K	-4.25M	3.27M	-595.68K	-881.52K	-52.45K	461.19K	-426.69K	-262.73K	970.98K
Change in Receivables	0	-3M	3M	0	0	0	0	0	0	0
Change in Inventory	0	-243.67K	8.18K	0	0	0	0	0	0	0
Change in Payables	943.91K	243.67K	-8.18K	-343.88K	-227.96K	-378.11K	457.13K	-347.95K	-263.57K	84.68K
Cash from Investing+	6.22K	-16.79K	-9.26K	22.5K	2K	0	0	-500K	0	0
Capital Expenditures	-1.66K	-16.79K	-9.26K	0	0	0	0	-500K	0	0
CapEx % of Revenue	-	0.01%	0%	-	-	-	-	0.29%	0%	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	7.88K	0	0	22.5K	2K	0	0	0	0	0
Cash from Financing+	3M	12.72M	125	1.48M	16.13M	5.43M	11.45M	0	0	0
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	8.97M	-125	1.48M	6.21K	0	3.68K	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-5.3M	-8.8M	1.48M	-6.46M	-6.4M	-4.27M	-4.74M	-5.15M	-4.11M	-2.82M
FCF Margin %	-	-2.93%	0.2%	-	-374.98%	-9.77%	-4.08%	-3.02%	-1.62%	-1.13%
FCF Growth %	0.57%	-0.66%	1.17%	-5.35%	0.01%	0.33%	-0.11%	-0.09%	0.2%	0.32%
FCF per Share	-150.64	-142.18	20.56	-85.50	-22.43	-6.68	-4.61	-3.62	-2.69	-1.83
FCF Conversion (FCF/Net Income)	0.42x	0.16x	-0.42x	0.89x	0.50x	0.39x	0.84x	0.71x	1.00x	0.71x
Interest Paid	0	0	0	0	8	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-146.38%	-475.95%	-23.6%	-60.3%	-94.19%	-74.03%	-36.88%	-40.9%	-35.27%	-50.12%
Return on Invested Capital (ROIC)	-96.67%	-374.59%	-25.63%	-60.27%	-119.27%	-274.51%	-929.13%	-1385.82%	-497.16%	-964.01%
Gross Margin	-	98.78%	97.94%	-	100%	100%	100%	100%	100%	100%
Net Margin	-	-1806.87%	-47.4%	-	-74856.59%	-2493.11%	-486.36%	-383.87%	-162.78%	-158.39%
Debt / Equity	0.06x	-	-	-	0.00x	0.01x	0.00x	-	-	-
Interest Coverage	-36.79x	-65.01x	-1963.02x	-301.53x	-	-	-	-	-	-
FCF Conversion	0.42x	0.16x	-0.42x	0.89x	0.50x	0.39x	0.84x	0.71x	1.00x	0.71x
Revenue Growth	-	-	152.83%	-100%	-	2460.31%	165.64%	47.06%	48.8%	-1.56%

Revenue by Segment

	2020
Royalty Revenue	437K
Royalty Revenue Growth	-

Frequently Asked Questions

Growth & Financials

Xenetic Biosciences, Inc. (XBIO) reported $2.9M in revenue for fiscal year 2024. This represents a 874% increase from $0.3M in 2012.

Xenetic Biosciences, Inc. (XBIO) saw revenue decline by 1.6% over the past year.

Xenetic Biosciences, Inc. (XBIO) reported a net loss of $3.2M for fiscal year 2024.

Dividend & Returns

Xenetic Biosciences, Inc. (XBIO) has a return on equity (ROE) of -50.1%. Negative ROE indicates the company is unprofitable.

Xenetic Biosciences, Inc. (XBIO) had negative free cash flow of $2.7M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Xenetic Biosciences, Inc. (XBIO) 10-Year Financial Performance & Capital Metrics

XBIO • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsHematologic Oncology

Revenue $3M -1.6%
EBITDA -$4M +10.3%
Net Income -$4M +4.2%
EPS (Diluted) -2.57 +5.2%
Gross Margin 100%
EBITDA Margin -162.03% +8.9%
Operating Margin -168.16% +5.4%
Net Margin -158.39% +2.7%
ROE -50.12% -42.1%
ROIC -964.01% -93.9%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 171.1%
✓Trading at only 0.6x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Weak momentum: RS Rating 12 (bottom 12%)
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y171.13%

3Y29.15%

TTM13.3%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM22.59%

EPS CAGR

10Y-

5Y-

3Y-

TTM22.64%

ROCE

10Y Avg-81.91%

5Y Avg-51.46%

3Y Avg-44.56%

Latest-53.21%

Peer Comparison

Hematologic Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
INCYIncyte Corporation	20.66B	105.24	701.60	14.76%	24.69%	25.55%	1.21%	0.01
TGTXTG Therapeutics, Inc.	4.88B	30.71	204.73	40.8%	13.31%	21.87%		1.14
AGIOAgios Pharmaceuticals, Inc.	1.62B	27.80	2.39	36.07%	-8.96%	-31.24%		0.04
CLRBCellectar Biosciences, Inc.	15.48M	3.65	-0.09			-200.99%		0.03
CASICASI Pharmaceuticals, Inc.	21.37M	1.04	-0.41	-15.77%	-183.93%	-301.8%		11.96
VORVor Biopharma Inc.	308.06M	14.06	-0.41			-94.52%		0.33
FATEFate Therapeutics, Inc.	121.12M	1.05	-0.64	-78.55%	-21.87%	-66.69%		0.27
KPTIKaryopharm Therapeutics Inc.	121.95M	6.66	-0.71	-0.55%	-87.43%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	3M	7.58M	0	17.07K	436.94K	1.16M	1.71M	2.54M	2.5M
Revenue Growth %	-	-	1.53%	-1%	-	24.6%	1.66%	0.47%	0.49%	-0.02%
Cost of Goods Sold+	56.12K	36.45K	156.12K	15.83K	0	0	0	0	0	0
COGS % of Revenue	-	0.01%	0.02%	-	-	-	-	-	-	-
Gross Profit+	-56.12K	2.96M	7.43M	-15.83K	17.07K	436.94K	1.16M	1.71M	2.54M	2.5M
Gross Margin %	-	0.99%	0.98%	-	1%	1%	1%	1%	1%	1%
Gross Profit Growth %	-	53.81%	1.51%	-1%	2.08%	24.6%	1.66%	0.47%	0.49%	-0.02%
Operating Expenses+	9.82M	50.43M	11M	7.28M	12.9M	14.37M	6.91M	8.42M	7.06M	6.7M
OpEx % of Revenue	-	16.81%	1.45%	-	756.12%	32.9%	5.95%	4.94%	2.78%	2.68%
Selling, General & Admin	6.39M	6.69M	6.94M	4.39M	4.73M	3.4M	3.74M	3.65M	3.56M	3.42M
SG&A % of Revenue	-	2.23%	0.91%	-	277.23%	7.78%	3.23%	2.14%	1.4%	1.37%
Research & Development	3.43M	43.74M	4.06M	2.88M	4.89M	1.73M	3.16M	4.77M	3.49M	3.29M
R&D % of Revenue	-	14.58%	0.54%	-	286.5%	3.96%	2.73%	2.79%	1.38%	1.32%
Other Operating Expenses	0	0	-41.1K	-24.64K	3.28M	9.24M	0	0	0	0
Operating Income+	-9.82M	-47.43M	-3.57M	-7.28M	-12.89M	-13.94M	-5.75M	-6.72M	-4.52M	-4.2M
Operating Margin %	-	-15.81%	-0.47%	-	-755.12%	-31.9%	-4.95%	-3.94%	-1.78%	-1.68%
Operating Income Growth %	0.24%	-3.83%	0.92%	-1.04%	-0.77%	-0.08%	0.59%	-0.17%	0.33%	0.07%
EBITDA+	-9.77M	-47.39M	-3.54M	-7.26M	-12.86M	-13.91M	-5.71M	-6.69M	-4.52M	-4.05M
EBITDA Margin %	-	-15.8%	-0.47%	-	-753.51%	-31.83%	-4.92%	-3.92%	-1.78%	-1.62%
EBITDA Growth %	0.24%	-3.85%	0.93%	-1.05%	-0.77%	-0.08%	0.59%	-0.17%	0.33%	0.1%
D&A (Non-Cash Add-back)	56.12K	36.45K	23.78K	15.83K	27.49K	28.84K	35.48K	27.04K	0	153.34K
EBIT	-9.82M	-53.48M	-3.59M	-7.28M	-9.6M	-4.69M	-5.75M	-6.72M	-4.52M	-4.2M
Net Interest Income+	-265.31K	-729.54K	14.73K	0	108.49K	126.17K	100.47K	167.15K	355.76K	249.86K
Interest Income	1.69K	32	16.54K	0	108.49K	126.17K	100.47K	167.15K	355.76K	249.86K
Interest Expense	267K	729.57K	1.82K	24.13K	0	0	0	0	0	0
Other Income/Expense	-2.69M	-6.78M	-26.37K	-24.13K	111.8K	125.68K	101.59K	165.56K	381.14K	244.15K
Pretax Income+	-12.51M	-54.21M	-3.6M	-7.3M	-12.78M	-13.81M	-5.65M	-6.55M	-4.13M	-3.96M
Pretax Margin %	-	-18.07%	-0.47%	-	-748.57%	-31.61%	-4.86%	-3.84%	-1.63%	-1.58%
Income Tax+	0	0	26.37K	24.13K	0	-2.92M	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	0.79%	1%	1%	1%	1%
Net Income+	-12.51M	-54.21M	-3.6M	-7.3M	-12.78M	-10.89M	-5.65M	-6.55M	-4.13M	-3.96M
Net Margin %	-	-18.07%	-0.47%	-	-748.57%	-24.93%	-4.86%	-3.84%	-1.63%	-1.58%
Net Income Growth %	0.13%	-3.33%	0.93%	-1.03%	-0.75%	0.15%	0.48%	-0.16%	0.37%	0.04%
Net Income (Continuing)	-12.51M	-54.21M	-3.6M	-7.3M	-12.78M	-10.89M	-5.65M	-6.55M	-4.13M	-3.96M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-355.34	-875.41	-49.78	-96.57	-55.92	-17.04	-5.39	-4.49	-2.71	-2.57
EPS Growth %	0.15%	-1.46%	0.94%	-0.94%	0.42%	0.7%	0.68%	0.17%	0.4%	0.05%
EPS (Basic)	-355.34	-875.41	-49.78	-96.58	-55.92	-17.04	-5.39	-4.49	-2.71	-2.57
Diluted Shares Outstanding	35.2K	61.92K	72.21K	75.6K	285.25K	639.24K	1.03M	1.42M	1.53M	1.54M
Basic Shares Outstanding	35.2K	61.92K	72.21K	75.59K	285.25K	639.24K	1.03M	1.42M	1.53M	1.54M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	4.19M	8.34M	5.88M	1.19M	11.09M	12.37M	18.72M	13.65M	9.59M	6.59M
Cash & Short-Term Investments	132.23K	4.05M	5.53M	571.61K	10.37M	11.53M	18.24M	13.1M	8.98M	6.17M
Cash Only	132.23K	4.05M	5.53M	571.61K	10.37M	11.53M	18.24M	13.1M	8.98M	6.17M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	3M	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	365	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	66.51K	66.51K	99.51K	66.51K	527.08K	0	227.04K	0	603.83K	0
Total Non-Current Assets+	12.72M	12.64M	13.28M	13.24M	10.46M	809.99K	1.09M	1.07M	1.02M	313.92K
Property, Plant & Equipment	62.02K	42.37K	27.85K	4.96K	20.8K	27.04K	0	0	0	0
Fixed Asset Turnover	-	70.81x	272.39x	-	0.82x	16.16x	-	-	-	-
Goodwill	3.28M	3.28M	3.28M	3.28M	0	0	0	0	0	0
Intangible Assets	9.24M	9.24M	9.24M	9.24M	9.24M	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	129.31K	66.34K	724.71K	705.66K	1.19M	782.94K	1.09M	1.07M	1.02M	313.92K
Total Assets+	16.91M	20.97M	19.16M	14.43M	21.55M	13.18M	19.82M	14.72M	10.61M	6.9M
Asset Turnover	-	0.14x	0.40x	-	0.00x	0.03x	0.06x	0.12x	0.24x	0.36x
Asset Growth %	0.04%	0.24%	-0.09%	-0.25%	0.49%	-0.39%	0.5%	-0.26%	-0.28%	-0.35%
Total Current Liabilities+	7.34M	1.87M	1.94M	1.6M	1.42M	936.93K	1.42M	1.07M	809.59K	894.26K
Accounts Payable	1.79M	1.01M	786.78K	934.15K	931.13K	327.4K	362.47K	287.36K	240.83K	283.62K
Days Payables Outstanding	11.63K	10.08K	1.84K	21.54K	-	-	-	-	-	-
Short-Term Debt	4.05M	0	0	0	20.04K	0	0	0	0	0
Deferred Revenue (Current)	1000K	0	0	0	0	0	0	0	0	0
Other Current Liabilities	19.1K	20.2K	44.31K	218.03K	463.99K	0	0	39.95K	48.26K	34.2K
Current Ratio	0.57x	4.47x	3.03x	0.75x	7.84x	13.20x	13.18x	12.72x	11.84x	7.37x
Quick Ratio	0.57x	4.47x	3.03x	0.75x	7.84x	13.20x	13.18x	12.72x	11.84x	7.37x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	2.96M	2.94M	2.92M	2.92M	2.92M	27.04K	0	0	0	0
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	27.04K	0	0	0	0
Deferred Tax Liabilities	2.92M	2.92M	2.92M	2.92M	2.92M	0	0	0	0	0
Other Non-Current Liabilities	38.79K	19.88K	0	0	0	0	0	0	0	0
Total Liabilities	10.3M	4.8M	4.86M	4.52M	4.33M	963.97K	1.42M	1.07M	809.59K	894.26K
Total Debt+	395K	0	0	0	20.04K	62.52K	27.04K	0	0	0
Net Debt	262.77K	-4.05M	-5.53M	-571.61K	-10.35M	-11.47M	-18.22M	-13.1M	-8.98M	-6.17M
Debt / Equity	0.06x	-	-	-	0.00x	0.01x	0.00x	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-36.79x	-65.01x	-1963.02x	-301.53x	-	-	-	-	-	-
Total Equity+	6.61M	16.17M	14.3M	9.91M	17.21M	12.22M	18.39M	13.65M	9.8M	6.01M
Equity Growth %	-0.37%	1.45%	-0.12%	-0.31%	0.74%	-0.29%	0.51%	-0.26%	-0.28%	-0.39%
Book Value per Share	187.75	261.13	198.04	131.12	60.35	19.11	17.89	9.59	6.41	3.90
Total Shareholders' Equity	6.61M	16.17M	14.3M	9.91M	17.21M	12.22M	18.39M	13.65M	9.8M	6.01M
Common Stock	162.01K	8.73K	9.04K	9.73K	6.09K	8.77K	13.46K	1.52K	1.54K	1.54K
Retained Earnings	-88.13M	-142.34M	-145.93M	-153.23M	-166.01M	-176.9M	-182.55M	-189.1M	-193.23M	-197.19M
Treasury Stock	-5.28M	-5.28M	-5.28M	-5.28M	-5.28M	-5.28M	-5.28M	-5.28M	-5.28M	-5.28M
Accumulated OCI	253.73K	253.73K	253.73K	253.73K	253.73K	253.73K	253.73K	253.73K	253.73K	253.73K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-5.3M	-8.79M	1.49M	-6.46M	-6.4M	-4.27M	-4.74M	-4.65M	-4.11M	-2.82M
Operating CF Margin %	-	-2.93%	0.2%	-	-374.98%	-9.77%	-4.08%	-2.72%	-1.62%	-1.13%
Operating CF Growth %	0.57%	-0.66%	1.17%	-5.33%	0.01%	0.33%	-0.11%	0.02%	0.11%	0.32%
Net Income	-12.51M	-54.21M	-3.6M	-7.3M	-12.78M	-10.89M	-5.65M	-6.55M	-4.13M	-3.96M
Depreciation & Amortization	56.12K	36.45K	23.78K	15.83K	27.49K	28.84K	35.48K	27.04K	0	0
Stock-Based Compensation	2.75M	2.1M	1.92M	1.42M	853.52K	468.91K	410.44K	511.48K	0	171.81K
Deferred Taxes	2.6M	-1.58M	0	0	0	-2.92M	-24.27K	0	0	0
Other Non-Cash Items	834K	49.11M	-126.32K	-5.23K	6.38M	9.1M	24.27K	1.79M	283.08K	0
Working Capital Changes	965.14K	-4.25M	3.27M	-595.68K	-881.52K	-52.45K	461.19K	-426.69K	-262.73K	970.98K
Change in Receivables	0	-3M	3M	0	0	0	0	0	0	0
Change in Inventory	0	-243.67K	8.18K	0	0	0	0	0	0	0
Change in Payables	943.91K	243.67K	-8.18K	-343.88K	-227.96K	-378.11K	457.13K	-347.95K	-263.57K	84.68K
Cash from Investing+	6.22K	-16.79K	-9.26K	22.5K	2K	0	0	-500K	0	0
Capital Expenditures	-1.66K	-16.79K	-9.26K	0	0	0	0	-500K	0	0
CapEx % of Revenue	-	0.01%	0%	-	-	-	-	0.29%	0%	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	7.88K	0	0	22.5K	2K	0	0	0	0	0
Cash from Financing+	3M	12.72M	125	1.48M	16.13M	5.43M	11.45M	0	0	0
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	8.97M	-125	1.48M	6.21K	0	3.68K	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-5.3M	-8.8M	1.48M	-6.46M	-6.4M	-4.27M	-4.74M	-5.15M	-4.11M	-2.82M
FCF Margin %	-	-2.93%	0.2%	-	-374.98%	-9.77%	-4.08%	-3.02%	-1.62%	-1.13%
FCF Growth %	0.57%	-0.66%	1.17%	-5.35%	0.01%	0.33%	-0.11%	-0.09%	0.2%	0.32%
FCF per Share	-150.64	-142.18	20.56	-85.50	-22.43	-6.68	-4.61	-3.62	-2.69	-1.83
FCF Conversion (FCF/Net Income)	0.42x	0.16x	-0.42x	0.89x	0.50x	0.39x	0.84x	0.71x	1.00x	0.71x
Interest Paid	0	0	0	0	8	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-146.38%	-475.95%	-23.6%	-60.3%	-94.19%	-74.03%	-36.88%	-40.9%	-35.27%	-50.12%
Return on Invested Capital (ROIC)	-96.67%	-374.59%	-25.63%	-60.27%	-119.27%	-274.51%	-929.13%	-1385.82%	-497.16%	-964.01%
Gross Margin	-	98.78%	97.94%	-	100%	100%	100%	100%	100%	100%
Net Margin	-	-1806.87%	-47.4%	-	-74856.59%	-2493.11%	-486.36%	-383.87%	-162.78%	-158.39%
Debt / Equity	0.06x	-	-	-	0.00x	0.01x	0.00x	-	-	-
Interest Coverage	-36.79x	-65.01x	-1963.02x	-301.53x	-	-	-	-	-	-
FCF Conversion	0.42x	0.16x	-0.42x	0.89x	0.50x	0.39x	0.84x	0.71x	1.00x	0.71x
Revenue Growth	-	-	152.83%	-100%	-	2460.31%	165.64%	47.06%	48.8%	-1.56%

Revenue by Segment

	2020
Royalty Revenue	437K
Royalty Revenue Growth	-

Frequently Asked Questions

Growth & Financials

Xenetic Biosciences, Inc. (XBIO) reported $2.9M in revenue for fiscal year 2024. This represents a 874% increase from $0.3M in 2012.

Xenetic Biosciences, Inc. (XBIO) saw revenue decline by 1.6% over the past year.

Xenetic Biosciences, Inc. (XBIO) reported a net loss of $3.2M for fiscal year 2024.

Dividend & Returns

Xenetic Biosciences, Inc. (XBIO) has a return on equity (ROE) of -50.1%. Negative ROE indicates the company is unprofitable.

Xenetic Biosciences, Inc. (XBIO) had negative free cash flow of $2.7M in fiscal year 2024, likely due to heavy capital investments.